New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:49 EDTOGEN, XONOragenics advancing towards identification of lead antibiotic clinical candidate
Oragenics (OGEN) announced that through its Exclusive Channel Collaboration with Intrexon Corporation (XON), it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 antibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon. Dr. John N. Bonfiglio, CEO of Oragenics, remarked, "The compounds we have selected for final evaluation align with our goal of identifying the first lead compound this year. We plan on meeting with the FDA later this year to discuss the IND enabling activities necessary to submit an IND application by mid-2015. Intrexon’s synthetic biology expertise in collaboration with our scientists has enabled generation of a large library of new potential MU1140 analogs with chemical and biological properties that differentiate from native MU1140. We remain very optimistic that these new lantibiotics will become useful in the fight against certain drug-resistant bacteria.”
News For OGEN;XON From The Last 14 Days
Check below for free stories on OGEN;XON the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
08:32 EDTXONIntrexon enters into technology collaboration with animal health company
Subscribe for More Information
July 22, 2014
07:15 EDTXONZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use